ArticleThe Journal of reproduction and development2024
Application of bovine progesterone intravaginal controlled-release formulation for estrus synchronization treatment in goats.
Article in The Journal of reproduction and development, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative efficacy of CIDR and intravaginal sponge synchronization with reduced sperm doses for laparoscopic artificial insemination in tropical goat production.Veterinary and animal science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Progesterone (P<inf>4</inf>)-impregnated controlled internal drug-releasing device for goats and sheep (CIDR-G) is used in the estrus synchronization protocol; however, it is not commercially available in Japan. In this study, we investigated whether a modification of CIDR-B, designed for cattle, could be used as a P<inf>4</inf> release device for synchronizing estrus in goats. An in vitro analysis showed that the dissolution rate was not significantly different between CIDR-G and modified CIDR-B (CIDR-M). The administration of CIDR-G or CIDR-M to dairy goats resulted in plasma P<inf>4</inf> concentrations being maintained at the functional luteal phase levels (>2 ng/ml) in both groups for 12 days after administration. However, P<inf>4</inf> concentrations at 2, 4, and 8 days after the administration of CIDR-G were significantly higher than those after the administration of CIDR-M. These results suggest that the CIDR-M examined in this study can maintain P<inf>4</inf> levels for 12 days after its administration as a P<inf>4</inf> release device.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.